**Supplementary Table 1.** Key baseline demographic and clinical characteristics (overall population, full analysis set)

|  |  |  |
| --- | --- | --- |
|  | **Vortioxetine (n = 309)** | **Desvenlafaxine (n = 293)** |
| Age (years) | 43.0 ± 12.7 | 43.5 ± 13.0 |
| Female | 214 (69.3) | 212 (72.4) |
| White | 284 (91.9) | 272 (92.8) |
| Paid employment or self-employed | 179 (57.9) | 181 (61.8) |
| Duration of current MDE (weeks) | 23.7 ± 9.2 | 23.7 ± 9.3 |
| Number of prior MDEs | 2.5 ± 1.9 | 2.6 ± 2.4 |
| Prior SSRIa |  |  |
| Citalopram | 26 (8.4) | 24 (8.2) |
| Escitalopram | 127 (41.1) | 122 (41.6) |
| Paroxetine | 46 (14.9) | 46 (15.7) |
| Sertraline | 112 (36.2) | 102 (34.8) |
| MADRS total score | 30.7 ± 3.7 | 30.7 ± 3.9 |
| CGI-S score | 4.5 ± 0.6 | 4.5 ± 0.6 |
| FAST total score | 41.5 ± 12.3 | 41.6 ± 12.9 |

Data are mean ± standard deviation or n (%).

a Some patients may have received more than one SSRI treatment for the current MDE.

CGI-S, Clinical Global Impression–Severity of Illness (score range = 1–7); FAST, Functioning Assessment Short Test (score range = 0–72); MADRS, Montgomery–Åsberg Depression Rating Scale (score range = 0–60); MDE, major depressive episode, SSRI, selective serotonin reuptake inhibitor.